Antwerp

Address

Middelheim General Hospital
Department of Neurology/Memory Clinic
Lindendreef 1
2020 Antwerpen
Phone: +32 3 280 31 11
Fax: +32 3 281 17 46

Contact

Principle Investigator and Director of Department
Prof. Dr. Peter Paul DeDeyn
Phone: +32 3 280 31 25 / 03 280 31 24 Secretary
Fax: +32 3 280 26 18
E-Mail: peter.dedeyn@ua.ac.be

Investigator
Dr. Rishi Sheorajpanday
Phone: +32 328 031 45
Fax: +32 3 280 31 41
E-Mail: Rishi.Sheorajpanday@zna.be

Link

Neurology Antwerp

Concept

At the ZNA Middelheim Hospital in Antwerp we aim to provide the best possible care for stroke victims and to conduct fundamental and clinical research at a high level.

For treatment of patients with acute stroke, a dedicated multidisciplinary stroke team and a stroke unit are available around the clock.

With regard to stroke research, we have two main fields of interest. In the Middelheim’s Interdisciplinary Stroke Study we evaluate the predictive value of clinical, biochemical, electrophysiological, and neuroimaging parameters for acute ischemic stroke. Further, we have a special interest in Fabry’s disease. In the Middelheim’s Fabry Study (MiFaS), we retrospectively evaluated the prevalence of Fabry’s disease in young patients with cryptogenic stroke. This project has been expanded to a prospective multi-center study on a national level, called the Belgian Fabry Study (BeFaS).

Publication

Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, Timmerman T, Vincent F, De Deyn PP. Middelheim Fabry Study (MiFaS): A retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg. In press.

Bath PM, Lindenstrom E, Boysen G, De Deyn P, Frijs P, Leys D, Marttila R, Olsson J, O’Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001 Sep 1;358(9283):702-10.